Genome sequencing of multiple primary tumors to reveal underlying germline cancer susceptibility.

IF 41.9 1区 医学 Q1 ONCOLOGY Journal of Clinical Oncology Pub Date : 2013-05-20 DOI:10.1200/JCO.2013.31.15_SUPPL.1552
K. Schrader, K. Stratton, R. Murali, Y. Laitman, L. Cavallone, Lily Offit, Y. Wen, Sohela Shah, R. Rau‐Murthy, C. Manschreck, E. Otegbeye, M. Corines, N. Kauff, R. Klein, M. Robson, Z. Stadler, E. Friedman, W. Foulkes, J. Vijai, K. Offit
{"title":"Genome sequencing of multiple primary tumors to reveal underlying germline cancer susceptibility.","authors":"K. Schrader, K. Stratton, R. Murali, Y. Laitman, L. Cavallone, Lily Offit, Y. Wen, Sohela Shah, R. Rau‐Murthy, C. Manschreck, E. Otegbeye, M. Corines, N. Kauff, R. Klein, M. Robson, Z. Stadler, E. Friedman, W. Foulkes, J. Vijai, K. Offit","doi":"10.1200/JCO.2013.31.15_SUPPL.1552","DOIUrl":null,"url":null,"abstract":"1552 Background: Apart from germline mutations in BRCA1 and BRCA2, the basis for genetic susceptibility to breast and ovarian cancer is heterogeneous, and can necessitate sequential or multiplex genetic testing. In addition, examination of germline DNA alone may not be conclusive. Information regarding both primary and secondary genetic events can be obtained from genomic analysis of tumors in conjunction with germline DNA. Methods: To determine the underlying cause of multiple primary malignancies in an Ashkenazi Jewish individual, whole genome sequencing was performed on DNA from the patient’s germline, invasive ductal carcinoma of the breast, and ovarian high-grade serous carcinoma. After identifying a structural variant of interest in this patient, germline DNA of 1846 Ashkenazi Jewish individuals who had a personal history of either breast, pancreatic, or ovarian cancer or a history of both breast and/or ovarian cancer and a similar family history, were screened using a TaqMan copy number assay or a ...","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"31 1","pages":"1552-1552"},"PeriodicalIF":41.9000,"publicationDate":"2013-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO.2013.31.15_SUPPL.1552","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

1552 Background: Apart from germline mutations in BRCA1 and BRCA2, the basis for genetic susceptibility to breast and ovarian cancer is heterogeneous, and can necessitate sequential or multiplex genetic testing. In addition, examination of germline DNA alone may not be conclusive. Information regarding both primary and secondary genetic events can be obtained from genomic analysis of tumors in conjunction with germline DNA. Methods: To determine the underlying cause of multiple primary malignancies in an Ashkenazi Jewish individual, whole genome sequencing was performed on DNA from the patient’s germline, invasive ductal carcinoma of the breast, and ovarian high-grade serous carcinoma. After identifying a structural variant of interest in this patient, germline DNA of 1846 Ashkenazi Jewish individuals who had a personal history of either breast, pancreatic, or ovarian cancer or a history of both breast and/or ovarian cancer and a similar family history, were screened using a TaqMan copy number assay or a ...
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多种原发肿瘤的基因组测序揭示潜在的种系癌症易感性。
1552背景:除了BRCA1和BRCA2的种系突变外,乳腺癌和卵巢癌的遗传易感性的基础是异质性的,可能需要进行序列或多重基因检测。此外,仅检查生殖系DNA可能无法得出结论。关于原发性和继发性遗传事件的信息可以从肿瘤基因组分析与种系DNA结合中获得。方法:为了确定阿什肯纳兹犹太人个体多重原发性恶性肿瘤的潜在原因,对患者生殖系、乳腺浸润性导管癌和卵巢高级别浆液性癌的DNA进行了全基因组测序。在确定了该患者感兴趣的结构变异后,使用TaqMan拷贝数测定法筛选了1846名德系犹太人的种系DNA,这些人有乳腺癌、胰腺癌或卵巢癌的个人病史,或有乳腺癌和/或卵巢癌的病史,并有类似的家族史。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Clinical Oncology
Journal of Clinical Oncology 医学-肿瘤学
CiteScore
41.20
自引率
2.20%
发文量
8215
审稿时长
2 months
期刊介绍: The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.
期刊最新文献
Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma-PUMP-2 Trial. North Star. NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. Good Oncologist: Doctoring Lessons From the Art of Oncology. Long-Term Prospective Cohort Study of Cervical Cancer Screening Using Triage of Women who Are Human Papillomavirus-Positive With Dual Stain and Human Papillomavirus Genotyping.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1